Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 4/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28052325 | 0.98 | BRD4 (0.46) | BRD4CYP2A6KEAP1MAP4K1ADORA2A | |
| SCHEMBL4251921 | 0.79 | RET (0.34) | BRD4CYP2A6KEAP1MAP4K1KDR | |
| SCHEMBL7921126 | 0.79 | BRD4 (0.50) | BRD4MAP4K1PIK3CGKDR | |
| SCHEMBL1683399 | 0.78 | BRD4 (0.49) | BRD4MAP4K1ADORA2AADORA1PIK3CG | |
| SCHEMBL23974709 | 0.76 | RIPK1 (0.31) | MAP4K1RIPK1 | |
| SCHEMBL15839990 | 0.76 | KIT (0.40) | RIPK1 | |
| SCHEMBL8357692 | 0.76 | BRD4 (0.47) | BRD4MAP4K1ADORA2AADORA1PIK3CG | |
| SCHEMBL2041171 | 0.76 | BRD4 (0.47) | BRD4MAP4K1PIK3CGHRH4KDR | |
| SCHEMBL2038921 | 0.76 | BRD4 (0.47) | BRD4MAP4K1PIK3CGKDRFGFR1 | |
| SCHEMBL2038785 | 0.76 | BRD4 (0.47) | BRD4MAP4K1ADORA2AADORA1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217965-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | PLEXXIKON INC. | 2024-07-04 | — | — | US | disclosed |
| US-11739088-B2 | Synthesis of heterocyclic compounds | PLEXXIKON INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9102672-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | GENMAB A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
| EP-2215074-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | The United States of America, as Represented by the Secretary, Department of Health and Human Services (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217965-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | CBR3, CBR1, CCNL2 | BRD4 129/4885CYP2A6 50/4885KEAP1 452/4885 |
| US-11739088-B2 | Synthesis of heterocyclic compounds | CBR3, CBR1, CCNL2 | BRD4 129/4885CYP2A6 50/4885KEAP1 452/4885 |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | BRD4 251/4885CYP2A6 2426/4885KEAP1 122/4885 |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | BRD4 251/4885CYP2A6 2426/4885KEAP1 122/4885 |
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | ERBB2, EGFR, ERBB3 | BRD4 2435/4885CYP2A6 3186/4885KEAP1 3742/4885 |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ABL1, ABL2, SRC | BRD4 1314/4885CYP2A6 2652/4885KEAP1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.